This morning, ATAI Life Sciences (Nasdaq: ATAI) experienced a shocking drop of nearly 40% in its stock price, plummeting to an all-time low since the company’s June 2021 Initial Public Offering. The cause? A failed lead asset from its majority-owned Perception Neuroscience unit.
Math over Myth is your weekly guide to stocks and ETFs in the psychedelic sector, this week focusing on the ETF PSIL
Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics
Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more
Get the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive
Track the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup
Psychedelic stock MindMed enters free fall as news of a private equity offering of common stock spooks retail investors
The psychedelic corporate shakeout continues as another company, HAVN Life Sciences, folds due to lack of cash flow
In the latest installment of Math Over Myth we navigate psychedelic stock MindMed’s reverse split with Fibonacci numbers
If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.